Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. A total of 238 women with breast cancer before age 50 or ovarian cancer at any age and at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results